A Study of AK111 in Subjects With Moderate-to-severe Plaque Psoriasis

Summary

This is a Phase Ib clinical study of multiple dose escalation of AK111 in subjects with moderate-to-severe plaque psoriasis

Timeline

Start

2020-05-28

Primary completion

2021-03-02

Completion

2021-03-02

Publications

• Jiang C, Zhou H, Zhang W, Xia Y, Li B, Ni X, Wang G, Zhang W, Chen B, He Z, Zhang M, Chen R, Jin H, Deng L. Efficacy, Safety and Pharmacokinetics of IL-17 Monoclonal Antibody Injection (AK111) in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blinded, Placebo-Controlled Phase Ib Multidose Escalation Clinical Study. Dermatol Ther (Heidelb). 2023 Feb;13(2):555-567. doi: 10.1007/s13555-022-00880-1. Epub 2022 Dec 24.

Drugs

Indications